Ankylosing spondylitis

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

TNFi Effectively Decreases Radiographic Progression in Early Ankylosing Spondylitis

By

Effective suppression of inflammation with tumor necrosis factor inhibitor therapy decreases radiographic progression in early ankylosing spondylitis.

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

Rates of Knee, Hip Arthroplasty Increasing Among Patients With Ankylosing Spondylitis

By

Researchers observed increased rates of both knee and hip arthroplasties in older patients with ankylosing spondylitis.

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

Lower Cardiorespiratory Fitness Associated With Increased CVD Risk in Ankylosing Spondylitis

By

Reduced cardiorespiratory fitness may be associated with increased risk for CVD in ankylosing spondylitis.

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

Risankizumab May Not Be Effective in Treatment of Ankylosing Spondylitis

By

Treatment with risankizumab was not effective in reducing the signs and symptoms of ankylosing spondylitis at 12 weeks.

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

Ankylosing Spondylitis Linked to Increased Prevalence of Left Ventricular Hypertrophy

By

Data strengthen the indication for performing a thorough CVD risk assessment in patients with inflammatory disorders.

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

Fatigue Affects Work Disability in Rheumatoid Arthritis, Ankylosing Spondylitis

By

Fatigue had a significant and independent effect on work disability measures in rheumatoid arthritis and ankylosing spondylitis.

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

Axial Psoriatic Arthritis and Ankylosing Spondylitis: Comparing Clinical, Radiologic Characteristics

By

It is unclear whether ankylosing spondylitis and axial psoriatic arthritis are part of a spectrum of the same disease, or whether they are separate diseases with overlapping features.

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

NSAID, TNFi Combination May Reduce Radiographic Progression in Ankylosing Spondylitis

By

Dose-related use of NSAIDs together with TNFi in patients with ankylosing spondylitis has a synergistic effect in slowing radiographic progression.

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

Biologic Therapy in Ankylosing Spondylitis: Insights From Social Media

By

Researchers used data from social media to identify concerns and perceptions regarding biologic therapies.

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

Tofacitinib Reduces MRI Inflammation, May Improve Outcomes in Ankylosing Spondylitis

By

Researchers assessed achievement of minimally important changes in SPARCC scores in biologic-naive patients with ankylosing spondylitis treated with tofacitinib or placebo.

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

Factors Associated With Neuropathic Pain in Ankylosing Spondylitis

By

A number of factors that include age, the presence of enthesitis, and depressive symptoms may be associated with neuropathic pain in ankylosing spondylitis.

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

Effects of Certolizumab Pegol Exposure on Pregnancy Outcomes in Women With Rheumatic Disease

By

Researchers sought to provide information on pregnancy outcomes, including major congenital malformations and other maternal and fetal adverse outcomes, in women treated with certolizumab pegol.

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

Biosimilar Etanercept SB4 May Decrease Disease Activity in Inflammatory Rheumatic Disease

By

Nonmandatory transitioning from originator etanercept to biosimilar etanercept SB4 using a specifically designed communication strategy showed a slightly lower persistence rate and smaller decreases in disease activity.

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

TNF Inhibitors Reduce Long-Term Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis

By

TNFi therapy yielded favorable results in patients with AS or PsA, with progressively better responses between 4 months and 3 years.

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

FDA Label Update for Certolizumab Pegol Affects Women of Childbearing Age

By

The FDA has approved a label update to include pharmacokinetic data showing low transfer of certolizumab pegol through placenta and minimal transfer to breast milk from mother to infant.

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

TNF Inhibitor Response in Women vs Men With Ankylosing Spondylitis

By

Investigators evaluated sex differences in the effectiveness of tumor necrosis factor inhibitors in patients with ankylosing spondylitis.

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

Spondyloarthritis Increases Risk for Dysrhythmias and Aortic Regurgitation

By

The risk for aortic regurgitation and cardiac rhythm abnormalities was evaluated in a nationwide cohort of patients with spondyloarthritis.

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

Sustained Reduction in axSpA Joint Inflammation With Certolizumab Pegol

By

Decreases in spinal and sacroiliac joint inflammation on MRI were maintained through 204 weeks with certolizumab pegol treatment.

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

Biologic DMARDs Do Not Reduce Spinal Fracture Risk in Ankylosing Spondylitis

By

Spinal fracture-free survival among patients with AS was not significantly affected by the use of bDMARD therapy.

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

Use of Secukinumab in Ankylosing Spondylitis: Efficacy and Safety

By

Investigators examined the long-term safety and efficacy of a subcutaneous maintenance dose of secukinumab 150 and 300 mg.

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

Do Biologic DMARDs Affect Spinal Fracture Risk in Ankylosing Spondylitis?

By

Male gender and the Charlson Comorbidity Index score contributed significantly to fracture risk in this population.

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

What Is the Best Site for Assessing Bone Loss in Ankylosing Spondylitis?

By

Research suggests that the best site to assess bone loss in patients with ankylosing spondylitis is the femoral neck.

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

Low-Dose CT Scans Detect Bone Proliferation in Ankylosing Spondylitis

By

Low-dose computed tomography detects more bone proliferation in patients with ankylosing spondylitis compared with conventional radiography.

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

Discontinuation of Biosimilar Infliximab Associated With Subjective Complaints

By

Transitioning from an originator agent to its biosimilar has the potential to reduce healthcare costs without compromising outcomes.

Etanercept for Spondyloarthritis: Impact on Disease Progression

Etanercept for Spondyloarthritis: Impact on Disease Progression

By

The use of tumor necrosis factor inhibitors to modify structural changes in axial spondyloarthritis may prevent progression to spinal disease.

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

Endothelial Function Improves With Methotrexate, Anti-TNF Therapy in Inflammatory Arthritis

By

Although the effect of antirheumatic drugs on inflammatory arthritic conditions has not been fully elucidated, treatment with methotrexate and tumor necrosis factor inhibitors has been found to improve endothelial dysfunction in this population.

Online Consultation System Benefits Rheumatic Disease Management

Online Consultation System Benefits Rheumatic Disease Management

The SSDM series of applications is cost-effective for patients of rheumatologists.

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

Long-Term Safety of Adalimumab in Immune-Related Diseases Analyzed

By

Investigators sought to determine the long-term safety of adalimumab use in patients with arthritis and other immune-related diseases.

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

Predictors of Accelerated Atherosclerosis in Spondyloarthritis Without Overt CVD

By

Predictors of subclinical accelerated atherosclerosis were examined in a recent study of patients with spondyloarthritis without overt cardiovascular disease.

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

Minimal Transfer of Certolizumab Pegol to Mature Breast Milk

By

The first lactation study of its kind evaluated whether a biologic drug is transferred into mature breast milk

Sign Up for Free e-newsletters